MURR to supply holmium-166 to NeoRx for PIII trial
NeoRx has executed an agreement with the University of Missouri-Columbia Research Reactor Center (MURR), under which MURR will manufacture and supply to NeoRx the radioisotope holmium-166 for NeoRx's phase III clinical trial of STR Skeletal Targeted Radiotherapy.
NeoRx has executed an agreement with the University of Missouri-Columbia Research Reactor Center (MURR), under which MURR will manufacture and supply to NeoRx the radioisotope holmium-166 for NeoRx's phase III clinical trial of STR Skeletal Targeted Radiotherapy.
NeoRx uses holmium-166 in the formulation of STR, its lead cancer therapeutic candidate, at its radiopharmaceutical manufacturing facility in Denton, Texas. MURR also supplied holmium-166 to NeoRx for its earlier clinical trials of STR.
'This agreement with MURR marks the continuation of a long and successful relationship between our two organisations, and provides NeoRx a reliable source of holmium for production of STR for the phase III registration trial,' said Jack Bowman, chairman and ceo of NeoRx.